Image pharmaphorum Editor Future of Generics The Falsified Medicines Directive – truly an opportunity for... Telling the fake from the true is often a challenge, particularly in this era of ‘fake news’. Views & Analysis Changing the shape of healthcare Kris Sterkens, company group chairman of Janssen EMEA, explains why pharma needs to be part of the solution. News FDA expands Keytruda approval for first-line NSCLC treatment Cancer drug Keytruda can now be used as a first-line treatment for patients with stage three non-small cell lung cancer (NSCLC), whose treatment options are limited. Views & Analysis Does your brand need behavioural science? Behavioural science has become a buzzword for pharma. Why? Because behaviour is a barrier to meeting brand objectives. Load more results
Future of Generics The Falsified Medicines Directive – truly an opportunity for... Telling the fake from the true is often a challenge, particularly in this era of ‘fake news’.
Views & Analysis Changing the shape of healthcare Kris Sterkens, company group chairman of Janssen EMEA, explains why pharma needs to be part of the solution.
News FDA expands Keytruda approval for first-line NSCLC treatment Cancer drug Keytruda can now be used as a first-line treatment for patients with stage three non-small cell lung cancer (NSCLC), whose treatment options are limited.
Views & Analysis Does your brand need behavioural science? Behavioural science has become a buzzword for pharma. Why? Because behaviour is a barrier to meeting brand objectives.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.